Benicar is an angiotensin receptor blocker (ARB) used to treat high blood pressure (hypertension).
It is sometimes given together with other blood pressure medications. Benicar is one of eight marketed ARB drugs, and the only one linked to sprue-like enteropathy.
Benicar was first approved for market in 2002. It is manufactured by Daiichi Sankyo.
The symptoms of Benicar enteropathy look very similar to those of Celiac Disease.
But, unlike Celiac Disease, a gluten-free lifestyle will not improve the symptoms.
The only way to improve Benicar enteropathy is by discontinuing the medication.
If you have experienced any of the following side effects and you have been prescribed Benicar for hypertension, contact your health care professional right away.
On July 4, 2013, the FDA issued a warning that Benicar causes sprue-like enteropathy.
According to the FDA warning, symptoms of sprue-like enteropathy include severe, chronic diarrhea with substantial weight loss.
The FDA approved changes to the labels of Benicar to include this concern.
The FDA previously sent Benicar manufacturer, Daiichi Sankyo, a warning regarding the manufacturer’s false advertising of Benicar.
In 2010, the FDA released a warning that Benicar may increase the risk of death in diabetic patients.
Prior to the FDA warning, in 2012 the Mayo Clinic in Rochester, Minnesota studied 22 patients hospitalized and presenting symptoms similar to celiac disease – unexplained chronic diarrhea, weight loss, and enteropathy.
But, unlike celiac disease, these patients were unable to control these symptoms with a gluten-free lifestyle and antibody blood tests did not support a diagnosis of celiac disease.
The Mayo Clinic discovered that each of the patients was prescribed Benicar for their hypertension.
Suspecting this was more than a coincidence, the Mayo clinic asked the severely injured patients to discontinue their use of Benicar.
After discontinuing Benicar, the patients confirmed that chronic diarrhea, vomiting, weight loss, and other intestinal inflammation symptoms improved.
Furthermore, after discontinuing Benicar, the patients gained an average of 27 pounds.
Following this link, an additional 40 patients have been determined to have Benicar-associated sprue-like enteropathy.
These numbers are likely to increase given the significant delay between the onset of severe sprue-like enteropathy and the start of the medication.
Multiple studies released in 2014 support a link between Benicar and sprue-like enteropathy.
If you have questions, contact TorHoerman Law.
TorHoerman Law was responsible for handling a medical case for our family. I was extremely impressed with their professionalism and ability to react quickly. They also did a nice job keeping us updated with the case throughout the process. This was the first time experiencing a situation like this and Tor Hoerman law did an excellent job from start to finish.
TorHoerman Law is an extraordinary law firm – a firm that truly makes the client’s best interests the primary concern. Their team of personal injury lawyers are experienced, personable, and well versed in a range of litigation areas. They are supported by a dedicated team of staff that are as equally friendly and helpful. I would recommend TorHoerman Law for any personal injury litigation needs.
All of my questions were answered quickly and in a way I could understand. Steve and the entire staff were friendly and professional.
I highly recommend this law firm! The attorneys and staff at THL worked hard, communicated every step of the process, kept me well informed at all times, and exceeded all expectations! The staff is kind, considerate, professional, and very experienced. Look no further, call now!
Top-notch, hardworking attorneys!
A wonderful and professional legal team. They helped me when I needed expert legal representation! Thank you TorHoerman Law!
They contacted me the next day. Very nice people!
The firm went above and beyond. Thank you for everything.
The attorneys at THL were extremely helpful with the legal aspects of setting up my small business.